Among NS-LUAD on the SD trajectory, KRAS mutations are the most prominent, occurring in 22/65 tumours (34%) and representing the strongest association with the SD trajectory in this group (Fig. 3b, Table S5, OR for enrichment in SD = 32.1, FDR = 2.8×10−13). Here, KRAS is linked to neoplasm.